In the Lab: Re­gen­eron brings its an­ti­body chops to gene edit­ing's biggest prob­lem, aim­ing to 'change the field'

Last year
R&D
In Focus

BioN­Tech nabs up to $90M for mpox vac­cine as it be­gins PhI/II tri­al be­hind Mod­er­na's lead

Last year
Financing
R&D

No­bel lau­re­ate Car­olyn Bertozzi joins cell ther­a­py biotech Ace­po­dia as chief sci­en­tif­ic ad­vi­sor

Last year
People

Did I ever tell you the one about the drunk­en biotech awards pro­gram I host­ed at a Chica­go bar?

Last year
Editor's note
Bioregnum

An­thos to stop fac­tor XI tri­al in atri­al fib­ril­la­tion ear­ly af­ter 'over­whelm­ing ben­e­fit'

Last year
R&D

Lon­za CEO Pierre-Alain Ruffieux to leave CD­MO amid re­duced growth

Last year
People
Manufacturing

Ex­clu­sive: Backed by Il­lu­mi­na, Bro­ken String Bio­sciences rais­es $15M to find off-tar­get gene ed­its

Last year
Financing
Startups

Mod­er­na's R&D game plan; 2sev­en­ty lay­offs amid CAR-T slow­down; Covid vac­cine boost­ers get thumbs up; and more

Last year
Weekly

FDA ap­proves GSK's JAK in­hibitor for rare blood can­cer af­ter three-month de­lay

Last year
R&D

DOJ, US Cham­ber lay out de­bate over drug price ne­go­ti­a­tion lit­i­ga­tion in Ohio court

Last year
Law

Lyn­dra lays off 23% of work­ers, to out­source man­u­fac­tur­ing as it ap­proach­es piv­otal read­out next month

Last year
People
Startups

No­var­tis share­hold­ers vote in fa­vor of San­doz spin­off, sep­a­ra­tion set for ear­ly Oc­to­ber

Last year
Pharma

EMA gives thumbs-down to GSK's mul­ti­ple myelo­ma drug, PTC's Duchenne can­di­date

Last year
Pharma
FDA+

Ken­vue, Wal­greens and oth­ers named in class ac­tion law­suits over ef­fi­ca­cy of nasal de­con­ges­tant

Last year
Pharma
Law

Almi­rall reimag­ines fa­mous works of art by da Vin­ci, Gau­guin and oth­ers in new AD cam­paign

Last year
Pharma
Marketing

Most phar­ma com­pa­nies are not ‘fu­ture ready’ as pres­sure mounts from AI ad­vances and IRA leg­is­la­tion, sur­vey ...

Last year
Pharma
Marketing

Bris­tol My­er­s' man­u­fac­tur­ing shut­down means low­er-than-ex­pect­ed Q3 sales for Abec­ma

Last year
Pharma
Manufacturing

FDA re­vers­es, plans to pull in­ter­change­abil­i­ty state­ment from la­bels of in­ter­change­able biosim­i­lars

Last year
FDA+

Nek­tar up­dates PhIb atopic der­mati­tis da­ta amid Lil­ly suit; Cure, Frac­etat join forces on AAV plat­form

Last year
News Briefing

Ab­cam finds founder’s op­po­si­tion to Dana­her deal ‘sur­pris­ing,’ say­ing he's sow­ing 'con­fu­sion for share­hold­er­s'

Last year
People
Deals

Late­com­er Am­gen takes 'plat­form ap­proach' in obe­si­ty as PhII da­ta loom

Last year
R&D
Pharma

Not 'TIL' 2024: Io­vance’s li­fileu­cel faces yet an­oth­er ap­proval de­lay, this time due to FDA re­source con­straints

Last year
Cell/Gene Tx
FDA+

Phil Vick­ers talks new role as head of Long­wood’s Solu af­ter Faze shut­down; Re­gen­eron CFO to re­tire in Feb­ru­ary

Last year
Peer Review

Neumo­ra, Rayze­Bio ride on­to Nas­daq in IPO dou­ble­head­er, breath­ing life in­to fall list­ings

Last year
Financing
Startups
First page Previous page 279280281282283284285 Next page Last page
A service from the Financial Times